Last week, Nektar announced that it has entered into a clinical trial collaboration and supply agreement with pharmaceutical giant… According to 4 analysts, the average rating for NKTR stock is “Sell.” The 12-month stock price forecast is $2.38, which is an increase of 207.69% from the latest price. Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review. Turning to the stock’s technical picture we see that short term indicators suggest on average that NKTR is a 100% Sell.

It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding.

NKTR underperformed the US Pharmaceuticals industry which returned 1.6% over the past year. Crane Co. will be added to the S&P MidCap 400 effective prior to the open of trading on Tuesday, April 4, replacing PacWest Bancorp which will be moved to the S&P SmallCap 600… Provide specific products and services to you, such as portfolio management or data aggregation. We’d like to share more about how we work and what drives our day-to-day business. Primecap Odyssey Growth’s successful high-conviction multimanager system contributes to its Gold rating. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.

These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. The P/E ratio of Nektar Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In the past three months, Nektar Therapeutics insiders have sold more of their company’s stock than they have bought.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The 1.50% of Nektar Therapeutics’s shares are in the hands of company insiders while institutional holders own 94.80% of the company’s shares.

The Academy Award winner discusses her newest role as Chief Communications Officer for the biotech company and the importance of taking care of your mental & physical health today. All values as of most recently reported quarter unless otherwise noted. Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one’s portfolio.

Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.45 loss in 2Q

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. In the market, a comparison of Nektar Therapeutics and its peers suggest the former has performed considerably weaker. Data shows NKTR’s intraday price has changed -1.95% in last session and -81.87% over the past year.

The group derives revenue from the United States and the Rest of the World. Real-time analyst ratings, insider transactions, earnings data, and more. Nektar Therapeutics has received a consensus rating of Sell. The company’s average rating score is 1.40, and is based on no buy ratings, 2 hold ratings, and 3 sell ratings.

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

Also important is the data on short interest which shows that short shares stood at 8.21 million on Apr 13, 2023, giving us a short ratio of 0.92. The data shows that as of Apr 13, 2023 short interest in Nektar Therapeutics stood at 4.34% of shares outstanding, with shares short rising to 7.08 million registered in Mar 14, 2023. Current price change has pushed the stock -65.27% YTD, which shows the potential for further growth is there.

• Investing.com – U.S. equities were higher at the close on Monday, as gains in the Consumer Services, Utilities and Basic Materials sectors propelled shares higher.
• Specifically, they have bought $0.00 in company stock and sold $121,158.00 in company stock.
• Maintaining independence and editorial freedom is essential to our mission of empowering investor success.
• They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.
• MarketBeat has tracked 3 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

CEO, President & Director recently sold US$65k worth of stock

The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In immunology, it is focused on addressing imbalances in the immune system to restore the body’s self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year.

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing … Nektar Therapeutics shares rallied late Monday after the biotech drug maker said it was cutting staff by 60% in San Francisco, where the company is based, and shifting its focus to immunology drugs in… Shares of Nektar Therapeutics Inc. were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb’s Opdivo. Shares of Nektar Therapeutics were down 5.7% in premarket trading on Tuesday, the day after the company said it will lay off 70% of its workforce. The technique has proven to be very useful for finding positive surprises.

92.30% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. MarketBeat has tracked 3 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week. Nektar Therapeutics has only been the subject of 4 research reports in the past 90 days. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

how to invest in bonds for beginnersNektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain… Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET.

Zacks.com featured highlights include Disney, Casey’s General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics

Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Utilities, Financials and Healthcare sectors propelled shares higher while losses in the Oil & Gas,… Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Telecoms, Oil & Gas and Consumer Services sectors propelled shares higher while losses in the Technology,… Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Oil & Gas, Financials and Basic Materials sectors propelled shares higher while losses in the Technology,… Investing.com – U.S. equities were higher at the close on Friday, as gains in the Healthcare, Industrials and Consumer Services sectors propelled shares higher.

There are currently 3 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “sell” NKTR shares. Nektar Therapeutics share price live 0.77, this page displays NASDAQ NKTR stock exchange data. View the NKTR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nektar Therapeutics real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NKTR quote.

You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of NKTR stock can currently be purchased for approximately $0.76. Only 1 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. 58 people have searched for NKTR on MarketBeat in the last 30 days.

On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category. Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Healthcare, Technology and Consumer Services sectors propelled shares higher while losses in the Oil & Gas,… Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Financials and Industrials sectors propelled shares higher. Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Oil & Gas, Telecoms and Financials sectors propelled shares higher while losses in the Utilities, Healthcare… Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Consumer Goods, Technology and Consumer Services sectors propelled shares higher while losses in the Oil &… Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Industrials, Oil & Gas and Technology sectors propelled shares lower.

It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Nektar Therapeutics 52 week low is $0.603 as of May 01, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Nektar Therapeutics 52 week high is $5.18 as of May 01, 2023.

https://1investing.in/ Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Basic Materials and Industrials sectors propelled shares higher. Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Healthcare, Technology and Utilities sectors propelled shares higher while losses in the Basic Materials,… Investing.com – U.S. equities were mixed at the close on Tuesday, as gains in the Oil & Gas, Healthcare and Technology sectors propelled shares higher while losses in the Telecoms,…